May 13, 2019
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
Apr 01, 2019
Amneal Announces Agreement with Zentiva to Divest Creo Pharma
Mar 12, 2019
Amneal Announces Launch of Rivastigmine Transdermal System
Mar 06, 2019
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Feb 28, 2019
Amneal Reports Fourth Quarter And Full Year 2018 Financial Results
Jan 24, 2019
Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019
Jan 22, 2019
Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer
Jan 14, 2019
Amneal Announces Approval of Rivastigmine Transdermal System
Dec 19, 2018
Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 21, 2018
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
Nov 12, 2018
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
Nov 12, 2018
Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine
Nov 07, 2018
Amneal Announces Solid Third Quarter 2018 Financial Results
Oct 25, 2018
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
Oct 24, 2018
Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa
Oct 23, 2018
Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
Oct 19, 2018
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
Sep 24, 2018
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 21, 2018
Amneal to Report Third Quarter 2018 Results on November 7, 2018
Sep 12, 2018
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP